Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy

Antimicrobial Agents and Chemotherapy
Luc J HuurnemanWilliam W Hope

Abstract

Voriconazole is the agent of choice for the treatment of invasive aspergillosis in children at least 2 years of age. The galactomannan index is a routinely used diagnostic marker for invasive aspergillosis and can be useful for following the clinical response to antifungal treatment. The aim of this study was to develop a pharmacokinetic-pharmacodynamic (PK-PD) mathematical model that links the pharmacokinetics of voriconazole with the galactomannan readout in children. Twelve children receiving voriconazole for treatment of proven, probable, and possible invasive fungal infections were studied. A previously published population PK model was used as the Bayesian prior. The PK-PD model was used to estimate the average area under the concentration-time curve (AUC) in each patient and the resultant galactomannan-time profile. The relationship between the ratio of the AUC to the concentration of voriconazole that induced half maximal killing (AUC/EC50) and the terminal galactomannan level was determined. The voriconazole concentration-time and galactomannan-time profiles were both highly variable. Despite this variability, the fit of the PK-PD model was good, enabling both the pharmacokinetics and pharmacodynamics to be described i...Continue Reading

References

Jan 25, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David W DenningHartmut Lode
Aug 9, 2002·The New England Journal of Medicine·Raoul HerbrechtUNKNOWN Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillu
Jul 18, 2003·Clinical Therapeutics·LilyAnn JeuHoratio B Fung
Oct 6, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Johan MaertensJohan Van Eldere
Jan 4, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andres PascualOscar Marchetti
Jan 8, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas J WalshUNKNOWN Infectious Diseases Society of America
May 9, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ben De PauwUNKNOWN National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
Apr 14, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Roger J M BrüggemannDavid M Burger
Dec 1, 2009·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·J W C AlffenaarD R A Uges
Dec 3, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael NeelyJill Hoffman
Mar 9, 2010·Trends in Microbiology·David W Denning, William W Hope
Aug 19, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Simone A NouérElias Anaissie
Feb 6, 2013·Antimicrobial Agents and Chemotherapy·William W HopeMichael N Neely
Jan 1, 2014·The Journal of Antimicrobial Chemotherapy·H Ruth AshbeeWilliam W Hope
Sep 17, 2014·Antimicrobial Agents and Chemotherapy·Marjolijn J P van WanrooyJan-Willem C Alffenaar
Mar 18, 2015·Antimicrobial Agents and Chemotherapy·Michael NeelyWilliam Hope

❮ Previous
Next ❯

Citations

Jun 30, 2016·Expert Review of Anti-infective Therapy·Kathleen M JobCatherine M T Sherwin
Dec 3, 2016·Journal of Pharmacokinetics and Pharmacodynamics·David S Bayard, Michael Neely
Dec 7, 2017·The Journal of Antimicrobial Chemotherapy·T M RawsonA H Holmes
Mar 22, 2018·Therapeutic Drug Monitoring·Timothy M RawsonAlison H Holmes
Oct 19, 2017·Antimicrobial Agents and Chemotherapy·Silke GastineGeorg Hempel
Sep 25, 2018·Journal of Clinical Pharmacology·Michael NeelyAndrea Edginton
Jan 29, 2019·Mycoses·Fabianne Altruda de Moraes Costa CarlesseAntonio Sergio Petrilli
Jul 7, 2017·Current Fungal Infection Reports·Adilia Warris, Thomas Lehrnbecher
Apr 20, 2018·Frontiers in Microbiology·Toine MercierJohan Maertens
Oct 5, 2018·European Journal of Drug Metabolism and Pharmacokinetics·Zorica JovićMarina Kostić
Dec 27, 2019·Pediatric Blood & Cancer·Sebastiaan D T SassenRon A A Mathôt
May 10, 2020·Intensive Care Medicine·Mohd H Abdul-AzizUNKNOWN Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC)
May 5, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Laura L KovandaWilliam W Hope
Feb 10, 2017·Journal of Pharmacokinetics and Pharmacodynamics·Laura L KovandaWilliam W Hope
Mar 25, 2020·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Anne-Grete MärtsonJan-Willem C Alffenaar
Jun 24, 2021·Nature Reviews. Microbiology·Timothy M RawsonAlison H Holmes

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.